Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Pharmaceutical Design
  4. Fast Track Articles
  5. Fast Track Article
image of Effect of Fibrates on Lipoprotein-associated Phospholipase A2 Mass and Activity: A Systematic Review and Meta-analysis of Controlled Clinical Trials

Abstract

Background

In vascular tissue, macrophages and inflammatory cells produce the enzyme lipoprotein-associated phospholipase A2 (Lp-PLA2). Treatment with fibrates decreases Lp-PLA2 levels in individuals with obesity and metabolic syndrome; however, these findings have not been fully clarified.

Objective

The goal of this study was to investigate the possible effects of fibrate therapy on Lp-PLA2 mass and activity through a meta-analysis of clinical trials.

Methods

Web of Science, PubMed, Scopus, Google Scholar, and ClinicalTrials.gov databases were searched using MeSH terms and keywords. Randomized controlled trials (RCT) evaluating the effect of statins on Lp- PLA2 mass and/or activity were included in the meta-analysis. Quantitative data were analyzed using a random-effects model and the generic inverse variance method.

Results

The meta-analysis of 10 clinical trials indicated that fibrate treatment has no significant effect on Lp- PLA2 mass (fibrate placebo/nothing = WMD: -3.29 ng/ml, 95% CI: -21.35, 14.78, 0.72; fibrate active control = WMD: -1.08 ng/ml, 95% CI: -51.38, 49.22, 0.97); Lp-PLA2 activity (fibrate active control = WMD: 0.84 nmol/ml/min, 95% CI: -0.17, 1.84, 0.10); HDL-LpPLA2 activity (fibrate active control = WMD: 0.77 nmol/ml/min, 95% CI: -0.33, 1.88, 0.17); and secretory PLA2 (fibrate active control = WMD: 0.37 ng/ml, 95% CI: -1.22, 1.97, 0.65). Also, the results of the sensitivity analysis were robust for all these parameters.

Conclusion

In conclusion, fibrate therapy did not reduce the mass and activity of Lp-PLA2.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128345231240925095400
2025-01-13
2025-04-02

  • From This Site

    /content/journals/cpd/10.2174/0113816128345231240925095400
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Tellis C.C. Tselepis A.D. Τhe role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2009 1791 5 327 338 10.1016/j.bbalip.2009.02.015 19272461
    [Google Scholar]
  2. Caslake M.J. Packard C.J. Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. Nat. Clin. Pract. Cardiovasc. Med. 2005 2 10 529 535 10.1038/ncpcardio0321 16186851
    [Google Scholar]
  3. MacPhee C.H. Moores K.E. Boyd H.F. Dhanak D. Ife R.J. Leach C.A. Leake D.S. Milliner K.J. Patterson R.A. Suckling K.E. Tew D.G. Hickey D.M.B. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: Use of a novel inhibitor. Biochem. J. 1999 338 2 479 487 10.1042/bj3380479 10024526
    [Google Scholar]
  4. Rosenson R.S. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome. Am. Heart J. 2008 155 3 499.e9 499.e16 10.1016/j.ahj.2007.12.012 18294485
    [Google Scholar]
  5. Kurniawan L.B. Rampo H. Soraya G.V. Adnan E. Esa T. Widaningsih Y. Bahrun U. Arif M. Effect of obesity, glucose control, lipid profiles, and blood pressure on Lp-PLA2 levels in type 2 diabetes mellitus patients. Obes. Med. 2021 22 100318 10.1016/j.obmed.2021.100318
    [Google Scholar]
  6. Jackisch L. Kumsaiyai W. Moore J.D. Al-Daghri N. Kyrou I. Barber T.M. Randeva H. Kumar S. Tripathi G. McTernan P.G. Differential expression of Lp-PLA2 in obesity and type 2 diabetes and the influence of lipids. Diabetologia 2018 61 5 1155 1166 10.1007/s00125‑018‑4558‑6 29427237
    [Google Scholar]
  7. Virani S.S. The Fibrates Story — A Tepid End to a PROMINENT Drug. N. Engl. J. Med. 2022 387 21 1991 1992 10.1056/NEJMe2213208 36342123
    [Google Scholar]
  8. Kim N.H. Kim S.G. Fibrates Revisited: Potential role in cardiovascular risk reduction. Diabetes Metab. J. 2020 44 2 213 221 10.4093/dmj.2020.0001 32347023
    [Google Scholar]
  9. Schoonjans K. Watanabe M. Suzuki H. Mahfoudi A. Krey G. Wahli W. Grimaldi P. Staels B. Yamamoto T. Auwerx J. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J. Biol. Chem. 1995 270 33 19269 19276 10.1074/jbc.270.33.19269 7642600
    [Google Scholar]
  10. Seth Loomba R. Arora R. Fibrates: Where are we now? Ther. Adv. Cardiovasc. Dis. 2009 3 1 91 96 10.1177/1753944708096281 19144670
    [Google Scholar]
  11. Okopień B. Buldak L. Bołdys A. Fibrates in the management of atherogenic dyslipidemia. Expert Rev. Cardiovasc. Ther. 2017 15 12 913 921 10.1080/14779072.2017.1408410 29183206
    [Google Scholar]
  12. Marx N. Sukhova G.K. Collins T. Libby P. Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999 99 24 3125 3131 10.1161/01.CIR.99.24.3125 10377075
    [Google Scholar]
  13. Muhlestein J.B. May H.T. Jensen J.R. Horne B.D. Lanman R.B. Lavasani F. Wolfert R.L. Pearson R.R. Yannicelli H.D. Anderson J.L. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: The DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J. Am. Coll. Cardiol. 2006 48 2 396 401 10.1016/j.jacc.2006.05.009 16843192
    [Google Scholar]
  14. Filippatos T.D. Gazi I.F. Liberopoulos E.N. Athyros V.G. Elisaf M.S. Tselepis A.D. Kiortsis D.N. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 2007 193 2 428 437 10.1016/j.atherosclerosis.2006.07.010 16911813
    [Google Scholar]
  15. Agouridis A.P. Tsimihodimos V. Filippatos T.D. Dimitriou A.A. Tellis C.C. Elisaf M.S. Mikhailidis D.P. Tselepis A.D. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. Expert Opin. Pharmacother. 2011 12 17 2605 2611 10.1517/14656566.2011.591383 21714585
    [Google Scholar]
  16. Robins S.J. Collins D. Nelson J.J. Bloomfield H.E. Asztalos B.F. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: The veterans affairs HDL intervention trial. Arterioscler. Thromb. Vasc. Biol. 2008 28 6 1172 1178 10.1161/ATVBAHA.107.160739 18356553
    [Google Scholar]
  17. Constantinides A. de Vries R. van Leeuwen J.J.J. Gautier T. van Pelt L.J. Tselepis A.D. Lagrost L. Dullaart R.P.F. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A2 mass in type 2 diabetes mellitus: Relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity. Eur. J. Intern. Med. 2012 23 7 633 638 10.1016/j.ejim.2012.05.008 22902096
    [Google Scholar]
  18. Thompson A. Gao P. Orfei L. Watson S. Di Angelantonio E. Kaptoge S. Ballantyne C. Cannon C.P. Criqui M. Cushman M. Hofman A. Packard C. Thompson S.G. Collins R. Danesh J. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: Collaborative analysis of 32 prospective studies. Lancet 2010 375 9725 1536 1544 10.1016/S0140‑6736(10)60319‑4 20435228
    [Google Scholar]
  19. Moher D. Shamseer L. Clarke M. Ghersi D. Liberati A. Petticrew M. Shekelle P. Stewart L.A. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst. Rev. 2015 4 1 1 10.1186/2046‑4053‑4‑1 25554246
    [Google Scholar]
  20. Sterne J.A.C. Savović J. Page M.J. Elbers R.G. Blencowe N.S. Boutron I. Cates C.J. Cheng H.Y. Corbett M.S. Eldridge S.M. Emberson J.R. Hernán M.A. Hopewell S. Hróbjartsson A. Junqueira D.R. Jüni P. Kirkham J.J. Lasserson T. Li T. McAleenan A. Reeves B.C. Shepperd S. Shrier I. Stewart L.A. Tilling K. White I.R. Whiting P.F. Higgins J.P.T. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 2019 366 l4898 10.1136/bmj.l4898 31462531
    [Google Scholar]
  21. Wan X. Wang W. Liu J. Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med. Res. Methodol. 2014 14 1 135 10.1186/1471‑2288‑14‑135 25524443
    [Google Scholar]
  22. Hozo S.P. Djulbegovic B. Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med. Res. Methodol. 2005 5 1 13 10.1186/1471‑2288‑5‑13 15840177
    [Google Scholar]
  23. Simental-Mendía L.E. Sánchez-García A. Linden-Torres E. Simental-Mendía M. Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: A meta-analysis of randomized controlled trials. Diabetes Res. Clin. Pract. 2021 177 108899 10.1016/j.diabres.2021.108899 34098057
    [Google Scholar]
  24. Saougos V.G. Tambaki A.P. Kalogirou M. Kostapanos M. Gazi I.F. Wolfert R.L. Elisaf M. Tselepis A.D. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler. Thromb. Vasc. Biol. 2007 27 10 2236 2243 10.1161/ATVBAHA.107.147280 17656665
    [Google Scholar]
  25. Wooten J.S. Nambi P. Gillard B.K. Pownall H.J. Coraza I. Scott L.W. Nambi V. Ballantyne C.M. Balasubramanyam A. Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients. Med. Sci. Sports Exerc. 2013 45 6 1043 1050 10.1249/MSS.0b013e3182843961 23299761
    [Google Scholar]
  26. Wägner A.M. Sánchez-Quesada J.L. Benítez S. Bancells C. Ordóñez-Llanos J. Pérez A. Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study. Diabetes Res. Clin. Pract. 2011 93 1 e25 e28 10.1016/j.diabres.2011.03.009 21440948
    [Google Scholar]
  27. Tsunoda F. Asztalos I.B. Horvath K.V. Steiner G. Schaefer E.J. Asztalos B.F. Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial. Atherosclerosis 2016 247 35 39 10.1016/j.atherosclerosis.2016.01.028 26854974
    [Google Scholar]
  28. Kei A. Liberopoulos E. Tellis C. Elisaf M. Tselepis A. Lipid-modulating treatments for mixed dyslipidemia increase HDL-associated phospholipase A2 activity with differential effects on HDL subfractions. Lipids 2013 48 10 957 965 10.1007/s11745‑013‑3826‑y 23949918
    [Google Scholar]
  29. Hogue J.C. Lamarche B. Tremblay A.J. Bergeron J. Gagné C. Couture P. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism 2008 57 3 380 386 10.1016/j.metabol.2007.10.014 18249211
    [Google Scholar]
  30. Hiukka A. Westerbacka J. Leinonen E.S. Watanabe H. Wiklund O. Hulten L.M. Salonen J.T. Tuomainen T.P. Yki-Järvinen H. Keech A.C. Taskinen M.R. Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. J. Am. Coll. Cardiol. 2008 52 25 2190 2197 10.1016/j.jacc.2008.09.049 19095138
    [Google Scholar]
  31. Ju H.B. Zhang F.X. Wang S. Song J. Cui T. Li L.F. Zhang H.Y. Effects of fenofibrate on inflammatory cytokines in diabetic retinopathy patients. Medicine (Baltimore) 2017 96 31 e7671 10.1097/MD.0000000000007671 28767589
    [Google Scholar]
  32. Kujiraoka T. Iwasaki T. Ishihara M. Ito M. Nagano M. Kawaguchi A. Takahashi S. Ishi J. Tsuji M. Egashira T. Stepanova I.P. Miller N.E. Hattori H. Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus. J. Lipid Res. 2003 44 10 2006 2014 10.1194/jlr.D300021‑JLR200 12867534
    [Google Scholar]
  33. Lalloyer F. Staels B. Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler. Thromb. Vasc. Biol. 2010 30 5 894 899 10.1161/ATVBAHA.108.179689 20393155
    [Google Scholar]
  34. Tsimihodimos V. Kakafika A. Tambaki A.P. Bairaktari E. Chapman M.J. Elisaf M. Tselepis A.D. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J. Lipid Res. 2003 44 5 927 934 10.1194/jlr.M200452‑JLR200 12611907
    [Google Scholar]
  35. Jakob T. Nordmann A.J. Schandelmaier S. Ferreira-González I. Briel M. Fibrates for primary prevention of cardiovascular disease events. Cochrane Libr. 2016 2017 3 CD009753 10.1002/14651858.CD009753.pub2 27849333
    [Google Scholar]
/content/journals/cpd/10.2174/0113816128345231240925095400
Loading
Effect of Fibrates on Lipoprotein-associated Phospholipase A2 Mass and Activity: A Systematic Review and Meta-analysis of Controlled Clinical Trials
Bentham Science Publishers ; https://doi.org/10.2174/0113816128345231240925095400
/content/journals/cpd/10.2174/0113816128345231240925095400
/content/journals/cpd/10.2174/0113816128345231240925095400
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: HDL-LpPLA2 ; meta-analysis ; Fibrates ; lipoprotein-associated phospholipase A2

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test